The development of CDK12/13 inhibitors, such as the irreversible covalent inhibitor THZ53120,32,33 and the noncovalent inhibitor SR-4835,16 has shown promise in inducing synthetic lethality in multiple cancer types.32 Here, CDK12 is linked to cancer.